GlobeNewsWire
06 Feb 2026, 16:55 UTC · 31w ago
Verdict
Headline takes no side. We score NORD +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Nordicus Partners Corporation has a pending application to uplist its common shares from the OTCQB to the Nasdaq Capital Market.
So whatUplisting to a major exchange typically increases liquidity, institutional ownership, and valuation for small-cap stocks.
More positive than 92% of claims this week
Orocidin's first pilot efficacy study in patients is anticipated to begin in Q3 2026 following the completion of GMP manufacturing.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Bio-Convert expects to complete its final GMP product by August 2026 and begin patient testing of QR-02 in Q3 2026.
More positive than 65% of claims this week
NoviThera is currently conducting a mouse study to determine if polypeptide levels drive psoriasis development, with results expected in approximately one month.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company provided positive updates on subsidiary clinical trials and its ongoing application to uplist to the Nasdaq.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
15h ago
−27.5%
Price is moving against the score
$3.30 vs $4.55 close before publication (Feb 5) · not market-adjusted
NORD chart →
